Sarepta Therapeutics reported $-228093000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Biogen BIIB:US $ 874.8M 28.6M
Biomarin Pharmaceutical BMRN:US $ 34.85M 8.66M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Capricor Therapeutics CAPR:US $ -7.11M 0.71M
Daiichi Sankyo 4568:JP Y 29415M 81785M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Insmed INSM:US $ -95144000 908K
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
IONIS PHARMACEUT IONS:US $ -103M 39M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Nektar Therapeutics NKTR:US $ -158.97M 68.7M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Newlink Genetics NLNK:US $ -7.72M 1.44M
Novavax NVAX:US $ -509.07M 715.14M
Ptc Therapeutics PTCT:US $ -148.7M 26.8M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Sanofi SAN:FP € 2660M 305M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Ultragenyx Pharmaceutical RARE:US $ -157.86M 6.1M